Avacta Group PLC (LON:AVCT)

Avacta Group PLC (LON:AVCT)

Share Price
29.70 p
0.2 (0.68 %)
Market Cap
£34.50 m
Proactive Investors - Run By Investors For Investors

Avacta Group PLC

Avacta’s principal focus is on its proprietary Affimer® platform, a novel engineered alternative to antibodies that has wide application in diagnostics, therapeutics and research.

Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer proteins, which can be quickly generated to bind with high specificity and affinity to a wide range of targets, have...

Market: AIM:AVCT
52-week High/Low: 51.000p / 21.000p
Sector: Pharma & Biotech
Market Cap: £34.50 m
Website: www.avacta.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Avacta Group PLC

Avacta Group PLC Timeline

CN Research

Avacta - interim results confirm progress

Avacta Group PLC (LON:AVCT) reported interim results to January 2019, confirming good progress on key development programmes Lead immune checkpoint inhibitor programmes continue to move towards in-man clinical data in 2020 Major development partnership and...
The US-listed group has triggered an exclusivity option. Chief executive Dr Alastair Smith said: "This is further strong validation of the potential of the Affimer drug platform to generate differentiated therapeutic molecules for development"
Capital Network analyst Riccardo Lowi discusses Avacta Group Plc (LON:AVCT) following the release of its preliminary results. Lowi says over the last year or so, management's delivered significant progress in bringing their Affimer platform into the commercial stage, across both therapeutics and diagnostic applications.
Capital Network analyst Riccardo Lowi discusses Avacta Group Plc's (LON:AVCT) development partnership with Bach BioSciences as well as the news it's making shares available via subscription and a placing to bring in £11.4mln. Lowi says the R&D collaboration with Bach is a very exiting step, potentially leading to...

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use